The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
In a small, open-label Phase II Hepatitis C study, an interferon-free and ribavirin-free combination of three direct-acting antivirals led to treatment success rates in the 90th percentile.
Continue reading »Data from Boehringer Ingelheim’s Phase III trial of faldaprevir claims high success rates for treatment-naïve patients with Hepatitis C genotype 1.
Continue reading »Sofosbuvir and ribavirin show a high response rate for Hepatitis C genotypes 2 and 3 in a Phase 3 study at Weil Cornell Medical Center.
Continue reading »
Telaprevir has helped many people conquer the Hepatitis C virus – but this medication is accompanied by a risk that should be widely known.
Continue reading »The polar opposite of what scientists previously thought, UCLA researchers have found that blocking an immune system protein could help the body clear a chronic viral infection.
Continue reading »Studies with and without interferon on faldaprevir (Boehringer Ingelheim’s Hepatitis C drug), will be presented at the EASL annual liver meeting this month.
Continue reading »Gilead has taken the next step for bringing an all-oral Hepatitis C treatment to fruition, submitting a new drug application to the FDA for their nucleotide analogue, sofosbuvir.
Continue reading »Two leading pharmaceutical companies, Vertex and Bristol-Myers Squibb, have agreed to work together towards their common goal – an all-oral Hepatitis C treatment.
Continue reading »Learn more about the phase 3 trial by Gilead Sciences Inc., which is evaluating once-daily fixed-dose combination of the nucleotide sofosbuvir and the NS5A inhibitor ledipasvir.
Continue reading »Discover why the most recent study on miravirsen offers hope for people with Hepatitis C.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
